PharmaEssentia Gets S&C’s Advice on $462 Million GDS Offering

PharmaEssentia Corp., a prominent biopharmaceutical business, completed its $462.7 million global depositary share (GDS) sale on April 18, making it Taiwan’s largest overseas biotech transaction. GDSs are traded on the Luxembourg Stock Exchange’s Euro MTF Market.

Ching-Yang Lin, Partner

PharmaEssentia produces and distributes medicinal treatments for MPN and other haematology and oncology illnesses. BESREMi®, the company’s principal medication, is approved for polycythemia vera treatment in 29 countries, including the US, EU, and Japan.

Jeffrey D. Hochberg, Partner

The S&C team advising Citigroup, J.P. Morgan, Morgan Stanley, Macquarie, UBS, and Yuanta as first GDS purchasers included Ching-Yang Lin, Stephen Pang, Hanzhi Wang, Henry Wong, and Hester Choi. Tax advisors were Jeffrey Hochberg, Saul Brander, and Tristan Hood. 40 Act advice came from Frederick Wertheim.

Saul Brander, Special Counsel

For detailed information, as well as the picture copyright, please see the law firm’s original article here: S&C Advises PharmaEssentia on $462 Million GDS Offering